{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000076","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.646806+00:00","generated_at":"2026-06-25T22:50:46.044897+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NeoGenomics Pharma Services President Dr. Gina Wallar resigns; Jennifer Rose named interim lead","bullets":["Dr. Gina M. Wallar resigns as President of Pharma Services Division effective May 27, 2022.","Jennifer Rose, current VP of Pharma Sales and Project Management, will assume interim responsibility starting May 27, 2022.","Ms. Rose joined NeoGenomics in December 2015."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000076","json":"https://secwatch.observer/filing/0001077183-22-000076.json","markdown":"https://secwatch.observer/filing/0001077183-22-000076.md","text":"https://secwatch.observer/filing/0001077183-22-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/0001077183-22-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/neo-20220502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:50:46.044897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89afad520a","claim":"Gina M. Wallar resigned as President, Pharma Services Division at NEOGENOMICS INC.","evidence_excerpt":"On May 2, 2022, Dr. Gina M. Wallar, NeoGenomics, Inc.’s (the “Company”) current President, Pharma Services Division, informed the Company of her intention to resign from her role effective May 27, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/0001077183-22-000076-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Pharma Services Division"}],"fact_type":"executive_change"},{"claim_id":"e5aea639a8","claim":"Jennifer Rose was appointed as Interim President, Pharma Services Division at NEOGENOMICS INC.","evidence_excerpt":"In connection with Dr. Wallar’s departure, Ms. Jennifer Rose will assume interim responsibility for the Pharma Services Division beginning on May 27, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/0001077183-22-000076-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"assume interim responsibility"},{"label":"Role","value":"Interim President, Pharma Services Division"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}